社区
首页
集团介绍
社区
资讯
行情
学堂
TigerAI
登录
注册
荣虎
IP属地：上海
+关注
帖子 · 63
帖子 · 63
关注 · 0
关注 · 0
粉丝 · 0
粉丝 · 0
荣虎
荣虎
·
01-20
$天然气主连 2602(NGmain)$
发生了什么？
看
602
回复
评论
点赞
1
编组 21备份 2
分享
举报
荣虎
荣虎
·
01-16
看好！但货少
看
178
回复
评论
点赞
1
编组 21备份 2
分享
举报
荣虎
荣虎
·
01-15
$BitGo Holdings, Inc.(BTGO)$
1180万股？估计只能分到0~3股。
看
1,882
回复
2
点赞
2
编组 21备份 2
分享
举报
荣虎
荣虎
·
2025-12-09
中了强子一手。 虽然发得贵了一点。 敬佩他像个男人，敢做敢为。 有社会责任。 资本运作搞得不错。
看
979
回复
评论
点赞
1
编组 21备份 2
分享
举报
荣虎
荣虎
·
2025-12-03
宝济原始股涌出，会跌破发行价吗？
看
390
回复
评论
点赞
1
编组 21备份 2
分享
举报
荣虎
荣虎
·
2025-12-03
请教港股打新高手，宝济“全流通”有无大风险？谢谢！
新股消息 | 宝济药业港股IPO及境内未上市股份“全流通”获中国证监会备案
智通财经APP获悉，10月29日，中国证监会国际合作司发布《关于上海宝济药业股份有限公司境外发行上市及境内未上市股份“全流通”备案通知书》。公司拟发行不超过110,426,740股境外上市普通股并在香
新股消息 | 宝济药业港股IPO及境内未上市股份“全流通”获中国证监会备案
看
448
回复
评论
点赞
1
编组 21备份 2
分享
举报
荣虎
荣虎
·
2025-12-02
明着干“坏事”的，都是善良之人👍
新股消息 | 宝济药业港股IPO及境内未上市股份“全流通”获中国证监会备案
智通财经APP获悉，10月29日，中国证监会国际合作司发布《关于上海宝济药业股份有限公司境外发行上市及境内未上市股份“全流通”备案通知书》。公司拟发行不超过110,426,740股境外上市普通股并在香
新股消息 | 宝济药业港股IPO及境内未上市股份“全流通”获中国证监会备案
看
704
回复
评论
点赞
1
编组 21备份 2
分享
举报
荣虎
荣虎
·
2025-12-02
明着干“坏事”的，都是善良之人👍
宝济药业港股IPO及境内未上市股份“全流通”获中国证监会备案
10月29日，中国证监会国际合作司发布《关于上海宝济药业股份有限公司境外发行上市及境内未上市股份“全流通”备案通知书》。公司拟发行不超过110,426,740股境外上市普通股并在香港联合交易 ...
宝济药业港股IPO及境内未上市股份“全流通”获中国证监会备案
看
681
回复
评论
点赞
1
编组 21备份 2
分享
举报
荣虎
荣虎
·
2025-10-07
请问，轩竹生物B可以打吗？谢谢。
看
1,071
回复
评论
点赞
1
编组 21备份 2
分享
举报
荣虎
荣虎
·
2025-10-06
长一倍 [强]
看
1,010
回复
评论
点赞
1
编组 21备份 2
分享
举报
加载更多
热议股票
{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"3565408688957143","uuid":"3565408688957143","gmtCreate":1602314666160,"gmtModify":1602314767999,"name":"荣虎","pinyin":"rhronghu","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/f68c97af871be1e637a52152c6750433","hat":"https://static.tigerbbs.com/f84d87792f02cf78e80ee34979fd31e5","hatId":"ca_profile_frame_5b7Fd6","hatName":"","vip":1,"status":2,"fanSize":2,"headSize":172,"tweetSize":63,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":2,"name":"无畏虎","nameTw":"無畏虎","represent":"初生牛犊","factor":"发布3条非转发主帖,1条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":23,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":3,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-3","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"偶像虎友","description":"加入老虎社区1500天","bigImgUrl":"https://static.tigerbbs.com/8b40ae7da5bf081a1c84df14bf9e6367","smallImgUrl":"https://static.tigerbbs.com/f160eceddd7c284a8e1136557615cfad","grayImgUrl":"https://static.tigerbbs.com/11792805c468334a9b31c39f95a41c6a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.11.19","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"02aa7f16703b4ce4ace6f1a7665789cc-1","templateUuid":"02aa7f16703b4ce4ace6f1a7665789cc","name":"知识体验官","description":"观看学堂课程满5节","bigImgUrl":"https://static.tigerbbs.com/fb5ae275631fb96a92d475cdc85d2302","smallImgUrl":"https://static.tigerbbs.com/c2660a1935bd2105e97c9915619936c3","grayImgUrl":null,"redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.08.06","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":2006},{"badgeId":"35ec162348d5460f88c959321e554969-2","templateUuid":"35ec162348d5460f88c959321e554969","name":"宗师交易员","description":"证券或期货账户累计交易次数达到100次","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.07.21","exceedPercentage":"80.10%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"228c86a078844d74991fff2b7ab2428d-3","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资合伙人虎","description":"证券账户累计交易金额达到100万美元","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.07.08","exceedPercentage":"93.54%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":6,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":4,"crmLevelSwitch":1,"location":"上海","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":4,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":523830637257768,"gmtCreate":1768914945618,"gmtModify":1768914950084,"author":{"id":"3565408688957143","authorId":"3565408688957143","name":"荣虎","avatar":"https://static.tigerbbs.com/f68c97af871be1e637a52152c6750433","crmLevel":4,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3565408688957143","idStr":"3565408688957143"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/FUT/NGmain\">$天然气主连 2602(NGmain)$ </a><v-v data-views=\"0\"></v-v> 发生了什么？","listText":"<a href=\"https://laohu8.com/FUT/NGmain\">$天然气主连 2602(NGmain)$ </a><v-v data-views=\"0\"></v-v> 发生了什么？","text":"$天然气主连 2602(NGmain)$ 发生了什么？","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/523830637257768","isVote":1,"tweetType":1,"viewCount":602,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":522431414776264,"gmtCreate":1768536294593,"gmtModify":1768536296961,"author":{"id":"3565408688957143","authorId":"3565408688957143","name":"荣虎","avatar":"https://static.tigerbbs.com/f68c97af871be1e637a52152c6750433","crmLevel":4,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3565408688957143","idStr":"3565408688957143"},"themes":[],"htmlText":"看好！但货少","listText":"看好！但货少","text":"看好！但货少","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/522431414776264","isVote":1,"tweetType":1,"viewCount":178,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":522131157213720,"gmtCreate":1768463364981,"gmtModify":1768463367039,"author":{"id":"3565408688957143","authorId":"3565408688957143","name":"荣虎","avatar":"https://static.tigerbbs.com/f68c97af871be1e637a52152c6750433","crmLevel":4,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3565408688957143","idStr":"3565408688957143"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/BTGO\">$BitGo Holdings, Inc.(BTGO)$ </a> 1180万股？估计只能分到0~3股。","listText":"<a href=\"https://laohu8.com/S/BTGO\">$BitGo Holdings, Inc.(BTGO)$ </a> 1180万股？估计只能分到0~3股。","text":"$BitGo Holdings, Inc.(BTGO)$ 1180万股？估计只能分到0~3股。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/522131157213720","isVote":1,"tweetType":1,"viewCount":1882,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"9000000000000632","authorId":"9000000000000632","name":"delusion梦碎","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"authorIdStr":"9000000000000632","idStr":"9000000000000632"},"content":"分这么点，太坑了吧！","text":"分这么点，太坑了吧！","html":"分这么点，太坑了吧！"}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":508914408268312,"gmtCreate":1765278025411,"gmtModify":1765278028824,"author":{"id":"3565408688957143","authorId":"3565408688957143","name":"荣虎","avatar":"https://static.tigerbbs.com/f68c97af871be1e637a52152c6750433","crmLevel":4,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3565408688957143","idStr":"3565408688957143"},"themes":[],"title":"","htmlText":"中了强子一手。 虽然发得贵了一点。 敬佩他像个男人，敢做敢为。 有社会责任。 资本运作搞得不错。","listText":"中了强子一手。 虽然发得贵了一点。 敬佩他像个男人，敢做敢为。 有社会责任。 资本运作搞得不错。","text":"中了强子一手。 虽然发得贵了一点。 敬佩他像个男人，敢做敢为。 有社会责任。 资本运作搞得不错。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/508914408268312","isVote":1,"tweetType":1,"viewCount":979,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":506685128823640,"gmtCreate":1764733084967,"gmtModify":1764736682943,"author":{"id":"3565408688957143","authorId":"3565408688957143","name":"荣虎","avatar":"https://static.tigerbbs.com/f68c97af871be1e637a52152c6750433","crmLevel":4,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3565408688957143","idStr":"3565408688957143"},"themes":[],"title":"","htmlText":"宝济原始股涌出，会跌破发行价吗？","listText":"宝济原始股涌出，会跌破发行价吗？","text":"宝济原始股涌出，会跌破发行价吗？","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/506685128823640","isVote":1,"tweetType":1,"viewCount":390,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":506684222346328,"gmtCreate":1764732888166,"gmtModify":1764732890743,"author":{"id":"3565408688957143","authorId":"3565408688957143","name":"荣虎","avatar":"https://static.tigerbbs.com/f68c97af871be1e637a52152c6750433","crmLevel":4,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3565408688957143","idStr":"3565408688957143"},"themes":[],"title":"","htmlText":"请教港股打新高手，宝济“全流通”有无大风险？谢谢！","listText":"请教港股打新高手，宝济“全流通”有无大风险？谢谢！","text":"请教港股打新高手，宝济“全流通”有无大风险？谢谢！","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/506684222346328","repostId":"2579970728","repostType":2,"repost":{"id":"2579970728","kind":"news","pubTimestamp":1761738339,"share":"https://www.laohu8.com/m/news/2579970728?lang=zh_CN&edition=full","pubTime":"2025-10-29 19:45","market":"us","language":"zh","title":"新股消息 | 宝济药业港股IPO及境内未上市股份“全流通”获中国证监会备案","url":"https://stock-news.laohu8.com/highlight/detail?id=2579970728","media":"智通财经","summary":"智通财经APP获悉，10月29日，中国证监会国际合作司发布《关于上海宝济药业股份有限公司境外发行上市及境内未上市股份“全流通”备案通知书》。公司拟发行不超过110,426,740股境外上市普通股并在香","content":"<p>智通财经APP获悉，10月29日，中国证监会国际合作司发布《关于上海宝济药业股份有限公司境外发行上市及境内未上市股份“全流通”备案通知书》。公司拟发行不超过110,426,740股境外上市普通股并在香港联合交易所上市。公司46名股东拟将所持合计116,415,550股境内未上市股份转为境外上市股份，并在香港联合交易所上市流通。</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/e82ea7ab80a2605d754d440d69904af5\" tg-width=\"1172\" tg-height=\"960\"></p><p>据招股书，宝济药业是一家处于临床阶段的<a href=\"https://laohu8.com/S/000504\">生物</a>技术公司，利用合成生物技术在中国开发及提供重组生物药物，专注于攻克治疗选择有限且药物制造工艺复杂的目标病症。自成立以来，该公司策略重点在于生产生物药物，通过替代源自动物器官、血液或尿液的生化提取产品，或以其他方式升级现有治疗手段，提升治疗标准。</p><p>截至2025年8月13日，该公司已打造出涵盖四个治疗领域的自研管线，由七款处于临床阶段的候选药物(包括三款核心产品KJ017、KJ103及SJ02)及五项临床前资产组成。该公司的核心产品在全球范围内受全面的知识产权保护，包括9项授权专利及10项专利申请。该公司以底盘细胞打造技术为支持，结合药物设计及生物制造能力建立专有技术平台。</p><p>该公司的技术平台使该公司能够在四个战略性治疗领域的候选药物开发中占据竞争地位，根据弗若斯特沙利文的资料，到2033年，临床可触及市场规模合计将超过人民币500亿元：大容量皮下给药，抗体介导的自身免疫性疾病，辅助生殖药物及以重组生物制药取代传统生化制品的变革性产品。该公司无法保证最终能够成功开发及上市该公司的核心产品。</p><p>附件：“全流通”股东名称及转换数量</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/9bcedc9f6071d9a9625c8826b3f779be\" tg-width=\"775\" tg-height=\"2622\"></p>","source":"stock_zhitongcaijing","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>新股消息 | 宝济药业港股IPO及境内未上市股份“全流通”获中国证监会备案</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n新股消息 | 宝济药业港股IPO及境内未上市股份“全流通”获中国证监会备案\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-10-29 19:45 北京时间 <a href=http://www.zhitongcaijing.com/content/detail/1362147.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，10月29日，中国证监会国际合作司发布《关于上海宝济药业股份有限公司境外发行上市及境内未上市股份“全流通”备案通知书》。公司拟发行不超过110,426,740股境外上市普通股并在香港联合交易所上市。公司46名股东拟将所持合计116,415,550股境内未上市股份转为境外上市股份，并在香港联合交易所上市流通。据招股书，宝济药业是一家处于临床阶段的生物技术公司，利用合成生物技术在...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1362147.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"02659":"宝济药业-B"},"source_url":"http://www.zhitongcaijing.com/content/detail/1362147.html","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2579970728","content_text":"智通财经APP获悉，10月29日，中国证监会国际合作司发布《关于上海宝济药业股份有限公司境外发行上市及境内未上市股份“全流通”备案通知书》。公司拟发行不超过110,426,740股境外上市普通股并在香港联合交易所上市。公司46名股东拟将所持合计116,415,550股境内未上市股份转为境外上市股份，并在香港联合交易所上市流通。据招股书，宝济药业是一家处于临床阶段的生物技术公司，利用合成生物技术在中国开发及提供重组生物药物，专注于攻克治疗选择有限且药物制造工艺复杂的目标病症。自成立以来，该公司策略重点在于生产生物药物，通过替代源自动物器官、血液或尿液的生化提取产品，或以其他方式升级现有治疗手段，提升治疗标准。截至2025年8月13日，该公司已打造出涵盖四个治疗领域的自研管线，由七款处于临床阶段的候选药物(包括三款核心产品KJ017、KJ103及SJ02)及五项临床前资产组成。该公司的核心产品在全球范围内受全面的知识产权保护，包括9项授权专利及10项专利申请。该公司以底盘细胞打造技术为支持，结合药物设计及生物制造能力建立专有技术平台。该公司的技术平台使该公司能够在四个战略性治疗领域的候选药物开发中占据竞争地位，根据弗若斯特沙利文的资料，到2033年，临床可触及市场规模合计将超过人民币500亿元：大容量皮下给药，抗体介导的自身免疫性疾病，辅助生殖药物及以重组生物制药取代传统生化制品的变革性产品。该公司无法保证最终能够成功开发及上市该公司的核心产品。附件：“全流通”股东名称及转换数量","news_type":1,"symbols_score_info":{"02659":2}},"isVote":1,"tweetType":1,"viewCount":448,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":506373418165288,"gmtCreate":1764657004380,"gmtModify":1764657006356,"author":{"id":"3565408688957143","authorId":"3565408688957143","name":"荣虎","avatar":"https://static.tigerbbs.com/f68c97af871be1e637a52152c6750433","crmLevel":4,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3565408688957143","idStr":"3565408688957143"},"themes":[],"title":"","htmlText":"明着干“坏事”的，都是善良之人👍","listText":"明着干“坏事”的，都是善良之人👍","text":"明着干“坏事”的，都是善良之人👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/506373418165288","repostId":"2579970728","repostType":2,"repost":{"id":"2579970728","kind":"news","pubTimestamp":1761738339,"share":"https://www.laohu8.com/m/news/2579970728?lang=zh_CN&edition=full","pubTime":"2025-10-29 19:45","market":"us","language":"zh","title":"新股消息 | 宝济药业港股IPO及境内未上市股份“全流通”获中国证监会备案","url":"https://stock-news.laohu8.com/highlight/detail?id=2579970728","media":"智通财经","summary":"智通财经APP获悉，10月29日，中国证监会国际合作司发布《关于上海宝济药业股份有限公司境外发行上市及境内未上市股份“全流通”备案通知书》。公司拟发行不超过110,426,740股境外上市普通股并在香","content":"<p>智通财经APP获悉，10月29日，中国证监会国际合作司发布《关于上海宝济药业股份有限公司境外发行上市及境内未上市股份“全流通”备案通知书》。公司拟发行不超过110,426,740股境外上市普通股并在香港联合交易所上市。公司46名股东拟将所持合计116,415,550股境内未上市股份转为境外上市股份，并在香港联合交易所上市流通。</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/e82ea7ab80a2605d754d440d69904af5\" tg-width=\"1172\" tg-height=\"960\"></p><p>据招股书，宝济药业是一家处于临床阶段的<a href=\"https://laohu8.com/S/000504\">生物</a>技术公司，利用合成生物技术在中国开发及提供重组生物药物，专注于攻克治疗选择有限且药物制造工艺复杂的目标病症。自成立以来，该公司策略重点在于生产生物药物，通过替代源自动物器官、血液或尿液的生化提取产品，或以其他方式升级现有治疗手段，提升治疗标准。</p><p>截至2025年8月13日，该公司已打造出涵盖四个治疗领域的自研管线，由七款处于临床阶段的候选药物(包括三款核心产品KJ017、KJ103及SJ02)及五项临床前资产组成。该公司的核心产品在全球范围内受全面的知识产权保护，包括9项授权专利及10项专利申请。该公司以底盘细胞打造技术为支持，结合药物设计及生物制造能力建立专有技术平台。</p><p>该公司的技术平台使该公司能够在四个战略性治疗领域的候选药物开发中占据竞争地位，根据弗若斯特沙利文的资料，到2033年，临床可触及市场规模合计将超过人民币500亿元：大容量皮下给药，抗体介导的自身免疫性疾病，辅助生殖药物及以重组生物制药取代传统生化制品的变革性产品。该公司无法保证最终能够成功开发及上市该公司的核心产品。</p><p>附件：“全流通”股东名称及转换数量</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/9bcedc9f6071d9a9625c8826b3f779be\" tg-width=\"775\" tg-height=\"2622\"></p>","source":"stock_zhitongcaijing","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>新股消息 | 宝济药业港股IPO及境内未上市股份“全流通”获中国证监会备案</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n新股消息 | 宝济药业港股IPO及境内未上市股份“全流通”获中国证监会备案\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-10-29 19:45 北京时间 <a href=http://www.zhitongcaijing.com/content/detail/1362147.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，10月29日，中国证监会国际合作司发布《关于上海宝济药业股份有限公司境外发行上市及境内未上市股份“全流通”备案通知书》。公司拟发行不超过110,426,740股境外上市普通股并在香港联合交易所上市。公司46名股东拟将所持合计116,415,550股境内未上市股份转为境外上市股份，并在香港联合交易所上市流通。据招股书，宝济药业是一家处于临床阶段的生物技术公司，利用合成生物技术在...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1362147.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"02659":"宝济药业-B"},"source_url":"http://www.zhitongcaijing.com/content/detail/1362147.html","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2579970728","content_text":"智通财经APP获悉，10月29日，中国证监会国际合作司发布《关于上海宝济药业股份有限公司境外发行上市及境内未上市股份“全流通”备案通知书》。公司拟发行不超过110,426,740股境外上市普通股并在香港联合交易所上市。公司46名股东拟将所持合计116,415,550股境内未上市股份转为境外上市股份，并在香港联合交易所上市流通。据招股书，宝济药业是一家处于临床阶段的生物技术公司，利用合成生物技术在中国开发及提供重组生物药物，专注于攻克治疗选择有限且药物制造工艺复杂的目标病症。自成立以来，该公司策略重点在于生产生物药物，通过替代源自动物器官、血液或尿液的生化提取产品，或以其他方式升级现有治疗手段，提升治疗标准。截至2025年8月13日，该公司已打造出涵盖四个治疗领域的自研管线，由七款处于临床阶段的候选药物(包括三款核心产品KJ017、KJ103及SJ02)及五项临床前资产组成。该公司的核心产品在全球范围内受全面的知识产权保护，包括9项授权专利及10项专利申请。该公司以底盘细胞打造技术为支持，结合药物设计及生物制造能力建立专有技术平台。该公司的技术平台使该公司能够在四个战略性治疗领域的候选药物开发中占据竞争地位，根据弗若斯特沙利文的资料，到2033年，临床可触及市场规模合计将超过人民币500亿元：大容量皮下给药，抗体介导的自身免疫性疾病，辅助生殖药物及以重组生物制药取代传统生化制品的变革性产品。该公司无法保证最终能够成功开发及上市该公司的核心产品。附件：“全流通”股东名称及转换数量","news_type":1,"symbols_score_info":{"02659":2}},"isVote":1,"tweetType":1,"viewCount":704,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":506373385159512,"gmtCreate":1764656975674,"gmtModify":1764656977985,"author":{"id":"3565408688957143","authorId":"3565408688957143","name":"荣虎","avatar":"https://static.tigerbbs.com/f68c97af871be1e637a52152c6750433","crmLevel":4,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3565408688957143","idStr":"3565408688957143"},"themes":[],"title":"","htmlText":"明着干“坏事”的，都是善良之人👍","listText":"明着干“坏事”的，都是善良之人👍","text":"明着干“坏事”的，都是善良之人👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/506373385159512","repostId":"2579516129","repostType":2,"repost":{"id":"2579516129","kind":"news","pubTimestamp":1761800220,"share":"https://www.laohu8.com/m/news/2579516129?lang=zh_CN&edition=full","pubTime":"2025-10-30 12:57","market":"sh","language":"zh","title":"宝济药业港股IPO及境内未上市股份“全流通”获中国证监会备案","url":"https://stock-news.laohu8.com/highlight/detail?id=2579516129","media":"智通财经","summary":"10月29日，中国证监会国际合作司发布《关于上海宝济药业股份有限公司境外发行上市及境内未上市股份“全流通”备案通知书》。公司拟发行不超过110,426,740股境外上市普通股并在香港联合交易 ...","content":"<p> 10月29日，中国证监会国际合作司发布《关于上海宝济药业股份有限公司境外发行上市及境内未上市股份“全流通”备案通知书》。公司拟发行不超过110,426,740股境外上市普通股并在香港联合交易所上市。公司46名股东拟将所持合计116,415,550股境内未上市股份转为境外上市股份，并在香港联合交易所上市流通。</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/c4abf261f0f735913756b9e4d3958ed9\" tg-width=\"1172\" tg-height=\"960\"></p><p> 据招股书，宝济药业是一家处于临床阶段的<a href=\"https://laohu8.com/S/000504\">生物</a>技术公司，利用合成生物技术在中国开发及提供重组生物药物，专注于攻克治疗选择有限且药物制造工艺复杂的目标病症。自成立以来，该公司策略重点在于生产生物药物，通过替代源自动物器官、血液或尿液的生化提取产品，或以其他方式升级现有治疗手段，提升治疗标准。</p><p> 截至2025年8月13日，该公司已打造出涵盖四个治疗领域的自研管线，由七款处于临床阶段的候选药物(包括三款核心产品KJ017、KJ103及SJ02)及五项临床前资产组成。该公司的核心产品在全球范围内受全面的知识产权保护，包括9项授权专利及10项专利申请。该公司以底盘细胞打造技术为支持，结合药物设计及生物制造能力建立专有技术平台。</p><p> 该公司的技术平台使该公司能够在四个战略性治疗领域的候选药物开发中占据竞争地位，根据弗若斯特沙利文的资料，到2033年，临床可触及市场规模合计将超过人民币500亿元：大容量皮下给药，抗体介导的自身免疫性疾病，辅助生殖药物及以重组生物制药取代传统生化制品的变革性产品。该公司无法保证最终能够成功开发及上市该公司的核心产品。</p><p> <strong>附件：“全流通”股东名称及转换数量</strong></p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/09742971538d029e1ad87199441b8e7a\" tg-width=\"775\" tg-height=\"2622\"></p><p><strong>关注<a href=\"https://laohu8.com/S/300033\">同花顺</a>财经（ths518），获取更多机会</strong></p>","source":"tonghuashun","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>宝济药业港股IPO及境内未上市股份“全流通”获中国证监会备案</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n宝济药业港股IPO及境内未上市股份“全流通”获中国证监会备案\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-10-30 12:57 北京时间 <a href=http://stock.10jqka.com.cn/hks/20251030/c672122041.shtml><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>10月29日，中国证监会国际合作司发布《关于上海宝济药业股份有限公司境外发行上市及境内未上市股份“全流通”备案通知书》。公司拟发行不超过110,426,740股境外上市普通股并在香港联合交易所上市。公司46名股东拟将所持合计116,415,550股境内未上市股份转为境外上市股份，并在香港联合交易所上市流通。 据招股书，宝济药业是一家处于临床阶段的生物技术公司，利用合成生物技术在中国开发及提供重组...</p>\n\n<a href=\"http://stock.10jqka.com.cn/hks/20251030/c672122041.shtml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"02659":"宝济药业-B"},"source_url":"http://stock.10jqka.com.cn/hks/20251030/c672122041.shtml","is_english":false,"share_image_url":"https://static.laohu8.com/f0343184bd9b9c963ed02b302442e2b8","article_id":"2579516129","content_text":"10月29日，中国证监会国际合作司发布《关于上海宝济药业股份有限公司境外发行上市及境内未上市股份“全流通”备案通知书》。公司拟发行不超过110,426,740股境外上市普通股并在香港联合交易所上市。公司46名股东拟将所持合计116,415,550股境内未上市股份转为境外上市股份，并在香港联合交易所上市流通。 据招股书，宝济药业是一家处于临床阶段的生物技术公司，利用合成生物技术在中国开发及提供重组生物药物，专注于攻克治疗选择有限且药物制造工艺复杂的目标病症。自成立以来，该公司策略重点在于生产生物药物，通过替代源自动物器官、血液或尿液的生化提取产品，或以其他方式升级现有治疗手段，提升治疗标准。 截至2025年8月13日，该公司已打造出涵盖四个治疗领域的自研管线，由七款处于临床阶段的候选药物(包括三款核心产品KJ017、KJ103及SJ02)及五项临床前资产组成。该公司的核心产品在全球范围内受全面的知识产权保护，包括9项授权专利及10项专利申请。该公司以底盘细胞打造技术为支持，结合药物设计及生物制造能力建立专有技术平台。 该公司的技术平台使该公司能够在四个战略性治疗领域的候选药物开发中占据竞争地位，根据弗若斯特沙利文的资料，到2033年，临床可触及市场规模合计将超过人民币500亿元：大容量皮下给药，抗体介导的自身免疫性疾病，辅助生殖药物及以重组生物制药取代传统生化制品的变革性产品。该公司无法保证最终能够成功开发及上市该公司的核心产品。 附件：“全流通”股东名称及转换数量关注同花顺财经（ths518），获取更多机会","news_type":1,"symbols_score_info":{"02659":2}},"isVote":1,"tweetType":1,"viewCount":681,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":486575547871416,"gmtCreate":1759821836793,"gmtModify":1759844859493,"author":{"id":"3565408688957143","authorId":"3565408688957143","name":"荣虎","avatar":"https://static.tigerbbs.com/f68c97af871be1e637a52152c6750433","crmLevel":4,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3565408688957143","idStr":"3565408688957143"},"themes":[],"htmlText":"请问，轩竹生物B可以打吗？谢谢。","listText":"请问，轩竹生物B可以打吗？谢谢。","text":"请问，轩竹生物B可以打吗？谢谢。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/486575547871416","isVote":1,"tweetType":1,"viewCount":1071,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":486226771440152,"gmtCreate":1759736822498,"gmtModify":1759736824858,"author":{"id":"3565408688957143","authorId":"3565408688957143","name":"荣虎","avatar":"https://static.tigerbbs.com/f68c97af871be1e637a52152c6750433","crmLevel":4,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3565408688957143","idStr":"3565408688957143"},"themes":[],"htmlText":"长一倍 [强]","listText":"长一倍 [强]","text":"长一倍 [强]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/486226771440152","isVote":1,"tweetType":1,"viewCount":1010,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"defaultTab":"posts","isTTM":false}